Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
300 women with expected poor ovarian response (POR) undergoing in vitro fertilization or
intra-cytoplasmic sperm injection (ICSI) will be randomly divided into 2 equal groups using
computer generated random numbers. Group 1 will receive Dehydroepiandrosterone (DHEA) 25 mg (
DHEA 25mg, Natrol , USA) t.d.s daily for 12 weeks before starting IVF/ICSI cycle and a
placebo similar to growth hormone (GH) daily from day 6 of stimulation until the day of human
chorionic gonadotrophin (hCG) trigger. Group 2 will receive an oral placebo t.d.s. daily for
12 weeks before ICSI in addition to GH (Somatotropin, Sedico, Egypt) 4 IU on day 6 of hMG
stimulation in a daily dose of 2.5 mg subcutaneous (SC) until the day of hCG triggering.
Patients included in the study will be subjected to full history taking and clinical
examination. On the second day of menstruation serum FSH, LH, Prolactin and Oestradiol will
be assessed and the antral follicular count (AFC) will be assessed using a vaginal ultrasound
scan. AFC will be defined as the number of follicles measuring 3-10mm.
All patients will have gonadotropin antagonist protocol with Human menopausal gonadotrophin
(hMG) stimulation until the day of hCG administration. On the day of hCG administration,
ovarian ultrasound scan will be performed using a transvaginal probe. Oocytes will be
aspirated 34-36 hours after HCG administration. Oocytes will be fertilized and embryos will
be transferred. Both groups will be compared regarding the proportion of ongoing pregnancy.